Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Intermittent Moxifloxacin + Standard Care: Moxifloxacin 400 mg orally once daily for 7 days every 8 weeks (total 6 cycles over 12 months), in addition to guideline-based standard care

Standard Care (in control arm): Participants will receive guideline-based management of bronchiectasis without long-term suppressive antibiotics.

Study summary

Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency.

This randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.

Eligibility

Primary outcome measure(s)

• Exacerbation frequency — 12 months
  Number of acute bronchiectasis exacerbations per patient during follow-up

Trial sites (1)

More Assiut University trials in Egypt